Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies

Author(s): Sheila Garcia-Rosa, Bianca de Freitas Brenha, Vinicius Felipe da Rocha, Ernesto Goulart, Bruno Henrique Silva Araujo*

Journal Name: Current Neuropharmacology

Volume 19 , Issue 6 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Epilepsy is the most common chronic neurologic disorder in the world, affecting 1-2% of the population. Besides, 30% of epilepsy patients are drug-resistant. Genomic mutations seem to play a key role in its etiology and knowledge of strong effect mutations in protein structures might improve prediction and the development of efficacious drugs to treat epilepsy. Several genetic association studies have been undertaken to examine the effect of a range of candidate genes for resistance. Although, few studies have explored the effect of the mutations into protein structure and biophysics in the epilepsy field. Much work remains to be done, but the plans made for exciting developments will hold therapeutic potential for patients with drug-resistance. In summary, we provide a critical review of the perspectives for the development of individualized medicine for epilepsy based on genetic polymorphisms/mutations in light of core elements such as transcriptomics, structural biology, disease model, pharmacogenomics and pharmacokinetics in a manner to improve the success of trial designs of antiepileptic drugs.

Keywords: Genetic epilepsy, brain organoids, transcriptome, single-cell sequencing, pharmacogenomics, drug resistance, drug development, antiepileptic drugs.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 6
Year: 2021
Page: [813 - 831]
Pages: 19
DOI: 10.2174/1570159X18666200915151909
Price: $95

Article Metrics

PDF: 28